Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.65 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.57 |
| ▸ | CCKBR | P32239 | 3/20 | 0.56 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083911 | 0.96 | CXCL8 (0.64) | CXCL8KISS1RCCKBRDPP3OPRM1 | |
| SCHEMBL30311066 | 0.95 | CXCL8 (0.63) | CXCL8CCKBRDPP3OPRM1 | |
| SCHEMBL30310984 | 0.89 | CXCL8 (0.57) | CXCL8CCKBR | |
| SCHEMBL30512655 | 0.88 | CXCL8 (0.62) | CXCL8KISS1ROPRM1 | |
| SCHEMBL31694497 | 0.88 | CXCR4 (0.64) | CXCL8KISS1R | |
| SCHEMBL30310961 | 0.88 | CXCL8 (0.61) | CXCL8KISS1RCCKBR | |
| SCHEMBL30949447 | 0.87 | CXCL8 (0.63) | CXCL8KISS1R | |
| SCHEMBL31053728 | 0.87 | KISS1R (0.56) | CXCL8KISS1RDPP3 | |
| SCHEMBL29416081 | 0.87 | DPP3 (0.58) | CXCL8KISS1RDPP3OPRM1 | |
| SCHEMBL29450205 | 0.86 | CXCL8 (0.62) | CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | CXCL8 1597/4885KISS1R 91/4885CCKBR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.